Prathyusha Konda

This study identifies fusion-driven oncogenic programs in translocation renal cell carcinoma (tRCC) that shape an immunosuppressive tumor microenvironment, explaining its reduced immunotherapy response.

This paper detects and monitors translocation renal cell carcinoma (tRCC) using plasma cell-free epigenomic profiling, achieving high accuracy in distinguishing tRCC from other cancers and healthy controls.

The paper identifies CDK9 inhibition as a therapeutic strategy for translocation renal cell carcinoma through phenotypic screening and mechanistic analysis.

This study identifies CDK4/6 and mTORC1 pathway activation in tRCC and shows that their dual inhibition synergistically suppresses tRCC cell growth in vitro and xenografts in vivo.

This study uses machine learning to infer gene dependencies from tumor transcriptomes, identifying cancer vulnerabilities in rare cancers without experimental screening.

This study identifies a genetic basis for cancer sex differences in Xp11 translocation renal cell carcinoma by showing a 2:1 female:male ratio in TFE3 fusions involving the inactive X chromosome.